Eisai, Inc. has plans for a new pharmaceutical production and formulation R&D facility for parenteral oncology treatments. Eisai has a number of drugs in development for patients with cancer. “Oncology is one of Eisai’s long-standing therapeutic areas of focus, supporting our human health care mission to increase benefits to patients and their families and satisfy unmet medical needs,” said Lonnel Coats, president and chief operating officer, Eisai “Our plans for...